REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Observational, retrospective, multicentre study in spanish patients with metastatic Renal
 Cell Carcinoma (mRCC) treated with sunitinib as a first-line treatment (treatment with
 previous cytokine therapy is accepted) according to clinical practice who obtained a complete
 response (CR) to treatment in one of these 2 situations:

 1. Complete response (CR) obtained exclusively with first-line sunitinib treatment
 (sunitinib CR).

 2. Response obtained after a period of time on treatment with sunitinib in which local
 treatment was also performed (surgery of the residual metastasis/metastases,
 radiofrequency ablation or radiotherapy) to achieve the total macroscopic disappearance
 of the disease, according to the opinion of the physician responsible for the patient
 (CR + local treatment).
Inclusion Criteria:

 1. Patients who are 18 year-old or over who have been treated for metastatic renal cell
 carcinoma with sunitinib as first-line treatment (treatment with prior cytokine
 therapy is accepted) between 2007 and 30 September 2018 and who have obtained as a
 best treatment response the total remission of the disease in the opinion of the
 doctor in charge from a clinical, radiological and/or macroscopic point of view. This
 response must have been reached through two possible strategies:

 A) Systemic treatment with sunitinib alone. B) Treatment with sunitinib and subsequent
 local treatment for one or more residual lesions that have not responded to the drug
 (traditional surgery, radiotherapy, SBRT (Stereotactic Body Radiation Therapy)).

 2. The duration of CR must have been confirmed with at least 2 consecutive imaging tests,
 without having a limit in the duration of this response. Although the patient had
 progressed subsequently, he/she may be included in this registry.

 3. Patients from any risk group

 4. Tumours of any histology

 Exclusion Criteria:

 1. Patients treated with another drug other than Sunitinib.

 2. Patients with no radiology reports proving CR.

 3. Patients with no record of the dose and regimen received with Sunitinib.

 4. Patients who achieved complete remission after 30 September 2018.